Campas-Moya Clara
Drugs Today (Barc). 2010 Jan;46(1):13-22. doi: 10.1358/dot.2010.46.1.1444434.
Tumor necrosis factor-alpha (TNF-alpha), a proinflammatory cytokine, has been implicated in the pathology of a variety of chronic autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. The introduction of TNF-alpha inhibitors represented a significant advance in the management of these diseases but the responses of individual patients to TNF-alpha inhibitors are not homogeneous and more therapeutic tools are needed. Golimumab (CNTO-148) is a novel anti-TNF-alpha human monoclonal antibody that blocks both soluble and transmembrane TNF-alpha. It is indicated in the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate, in adults with active and progressive psoriatic arthritis either alone or in combination with methotrexate, and in adult patients with active ankylosing spondylitis who have had an inadequate response to conventional therapies. Golimumab has generally been well tolerated in clinical trials with a safety profile comparable to other currently available TNF-alpha inhibitors. Its advantages are that it can be administered s.c. once monthly, it is labeled for patient self-administration and is suitable for both s.c. and i.v. administration. Golimumab is currently being investigated in other chronic inflammatory diseases.
肿瘤坏死因子-α（TNF-α）是一种促炎细胞因子，与多种慢性自身免疫性疾病的病理过程有关，如类风湿性关节炎、银屑病关节炎和强直性脊柱炎。TNF-α抑制剂的引入是这些疾病治疗方面的一项重大进展，但个体患者对TNF-α抑制剂的反应并不一致，因此需要更多的治疗手段。戈利木单抗（CNTO-148）是一种新型抗TNF-α人单克隆抗体，可阻断可溶性和跨膜TNF-α。它适用于联合甲氨蝶呤治疗中度至重度活动性类风湿性关节炎的成人患者，单独或联合甲氨蝶呤治疗活动性和进行性银屑病关节炎的成人患者，以及对传统疗法反应不足的活动性强直性脊柱炎成年患者。在临床试验中，戈利木单抗总体耐受性良好，其安全性与其他现有TNF-α抑制剂相当。它的优点是可以每月皮下注射一次，有患者自我给药的标签，适用于皮下注射和静脉注射。目前正在对戈利木单抗在其他慢性炎症性疾病中的应用进行研究。
